Literature DB >> 35832982

K i -67/MIB-1 and Recurrence in Pituitary Adenoma.

Kent Tadokoro1, Colten Wolf1, Joseph Toth2, Cara Joyce3, Meharvan Singh4, Anand Germanwala5, Chirag Patel1.   

Abstract

Objectives  K i -67/MIB-1 is a marker of cellular proliferation used as a pathological parameter in the clinical assessment of pituitary adenomas, where its expression has shown utility in predicting the invasiveness of these tumors. However, studies have shown variable results when using K i -67/MIB-1 association with recurrence. The purpose of this study is to determine if a high K i -67/MIB-1 labeling index (LI) is predictive of recurrence in pituitary adenomas. Methods  A retrospective chart review was performed for patients undergoing pituitary adenoma resection with at least 1 year of follow-up. Additionally, systematic data searches were performed and included studies that correlated recurrence rate to K i -67/MIB-1 LI. Our institutional data were included in a synthesis with previously published data. Results  Our institutional review included 79 patients with a recurrence rate of 26.6%. We found that 8.8% of our patients had a high K i -67/MIB-1 LI (>3%); however, high K i -67/MIB-1 was not associated with recurrence. The systematic review identified 244 articles and 49 full-text articles that were assessed for eligibility. Quantitative analysis was performed on 30 articles including our institutional data and 18 studies reported recurrence by level of K i -67/MIB-1 LI. Among studies that compared K i -67/MIB-1 ≥3 vs. <3%, 10 studies reported odds ratios (OR) greater than 1 of which 6 were statistically significant. A high K i -67/MIB-1 had higher odds of recurrence via the pooled odds ratio (OR = 4.15, 95% confidence interval [CI]: 2.31-7.42). Conclusion  This systematic review suggests that a high K i -67/MIB-1 should prompt an increased duration of follow-up due to the higher odds of recurrence of pituitary adenoma. Thieme. All rights reserved.

Entities:  

Keywords:  K i -67 ; MIB-1; pituitary adenoma; recurrence

Year:  2021        PMID: 35832982      PMCID: PMC9272325          DOI: 10.1055/s-0041-1735874

Source DB:  PubMed          Journal:  J Neurol Surg B Skull Base        ISSN: 2193-634X


  59 in total

1.  Pituitary tumor transforming gene and insulin-like growth factor 1 receptor expression and immunohistochemical measurement of Ki-67 as potential prognostic markers of pituitary tumors aggressiveness.

Authors:  Laura Sánchez-Tejada; Ruth Sánchez-Ortiga; Oscar Moreno-Pérez; Carmen Fajardo Montañana; Maria Niveiro; Nicholas A Tritos; Antonio M Picó Alfonso
Journal:  Endocrinol Nutr       Date:  2013-02-15

2.  Recurrence in pituitary adenomas in childhood and adolescence.

Authors:  A J Espay; B Azzarelli; L S Williams; J B Bodensteiner
Journal:  J Child Neurol       Date:  2001-05       Impact factor: 1.987

3.  Clinical and Pathologic Characteristics Predicted the Postoperative Recurrence and Progression of Pituitary Adenoma: A Retrospective Study with 10 Years Follow-Up.

Authors:  Liang Lv; Senlin Yin; Peizhi Zhou; Yu Hu; Cheng Chen; Weichao Ma; Yong Jiang; Zeming Wang; Shu Jiang
Journal:  World Neurosurg       Date:  2018-07-04       Impact factor: 2.104

4.  Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study.

Authors:  Mariagiovanna Filippella; Françoise Galland; Michèle Kujas; Jacques Young; Antongiulio Faggiano; Gaetano Lombardi; Annamaria Colao; Geri Meduri; Philippe Chanson
Journal:  Clin Endocrinol (Oxf)       Date:  2006-10       Impact factor: 3.478

5.  Ki67 Labeling Correlated With Invasion But Not With Recurrence.

Authors:  Alireza Sadeghipour; Leily Mahouzi; Mohammad M Salem; Shaghayegh Ebrahim-Nejad; Mohsen Asadi-Lari; Amir Radfar; Irina Filip; Pegah Babaheidarian
Journal:  Appl Immunohistochem Mol Morphol       Date:  2017 May/Jun

6.  Prognostic significance of MIB-1, p53, and bcl-2 immunoreactivity in meningiomas.

Authors:  E Karamitopoulou; E Perentes; M Tolnay; A Probst
Journal:  Hum Pathol       Date:  1998-02       Impact factor: 3.466

7.  Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy.

Authors:  M C Bettencourt; J J Bauer; I A Sesterhenn; F K Mostofi; D G McLeod; J W Moul
Journal:  J Urol       Date:  1996-09       Impact factor: 7.450

Review 8.  Advances in the treatment of prolactinomas.

Authors:  Mary P Gillam; Mark E Molitch; Gaetano Lombardi; Annamaria Colao
Journal:  Endocr Rev       Date:  2006-05-26       Impact factor: 19.871

9.  A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up.

Authors:  Jacqueline Trouillas; Pascal Roy; Nathalie Sturm; Emmanuelle Dantony; Christine Cortet-Rudelli; Gabriel Viennet; Jean-François Bonneville; Richard Assaker; Carole Auger; Thierry Brue; Aurélie Cornelius; Henry Dufour; Emmanuel Jouanneau; Patrick François; Françoise Galland; François Mougel; François Chapuis; Laurent Villeneuve; Claude-Alain Maurage; Dominique Figarella-Branger; Gérald Raverot; A Barlier; M Bernier; F Bonnet; F Borson-Chazot; G Brassier; S Caulet-Maugendre; O Chabre; P Chanson; J F Cottier; B Delemer; E Delgrange; L Di Tommaso; S Eimer; S Gaillard; M Jan; J J Girard; V Lapras; H Loiseau; J G Passagia; M Patey; A Penfornis; J Y Poirier; G Perrin; A Tabarin
Journal:  Acta Neuropathol       Date:  2013-02-12       Impact factor: 17.088

10.  Growth fractions (Ki-67) in primary breast cancers, with particular reference to node-negative tumors.

Authors:  W Weikel; C Brumm; C Wilkens; T Beck; P G Knapstein
Journal:  Cancer Detect Prev       Date:  1995
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.